Viability of Breast Conservation Therapy Gives Patients ‘More of a Choice,’ Says Expert

Video

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota indicated that breast conservation therapy, if it can be proven as a reasonable option for patients with multiple ipsilateral breast cancer, could offer patients more choice in treatment.

Demonstrating breast conservation surgery as a reasonable option for patients with multiple ipsilateral breast cancer may give women more of a choice in terms of treatment, according to Judy C. Boughey, MD.

During the 2022 San Antonio Breast Cancer Symposium (SABCS), CancerNetwork® spoke with Boughey, a surgical oncologist of the Division of Breast and Melanoma Surgical Oncology and the Department of Surgery at Mayo Clinic in Rochester, Minnesota, about the historical reasons why mastectomy is still used today and the potential impact of breast conservation therapy on local recurrence rates.

As such, Boughey and her colleagues aimed to assess the efficacy of breast conservation therapy as part of the phase 2 ACOSOG Z11102 (NCT01556243).

Transcript:

Women who have multiple ipsilateral breast cancer are often recommended for mastectomy. And this is based off the literature that historically showed a high rate of local recurrence in the breast; patients were treated with breast conservation if they had more than one foci of disease in the breast.

However, some more recent contemporary single institution studies have been reassuring and showing some lower local recurrence rates with the use of breast conserving surgery in patients with multiple ipsilateral breast cancer. We thought that this was an important question to ask for our patients in a prospective clinical trial.

We're seeing more and more patients who are being worked up for breast cancer and then being diagnosed with multiple foci of disease in the breast [due to] advances in screening, increased use of screening, and improvements in not only the screening modalities, but also diagnostic modalities, as well as the use of MRI.

With more use of MRI, you've got a higher likelihood of finding a second small foci elsewhere in the breast, [which] then at times commits the patient to require a mastectomy. If we could show that breast conservation surgery was a reasonable option for these women, then these women would have more of a choice.

Reference

Boughey JC, Rosenkranz KM, Ballman KV, et al. Impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer – results from ACOSOG Z11102 (Alliance). Presented at the 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX; abstract GS4-01.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content